Cocrystal Pharma, Inc. — Income Charts
31 quarters of history · ending 2020-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+26.9% +$108K
$510K
Cost of Revenue
$977K
Gross Profit
$1M
R&D↓-27.1% -$260K
$698K
D&A↑+55.2% +$16K
$45K
Operating Income↓-49.8% -$901K
$-3M
EBITDA↑+55.2% +$16K
$45K
Interest Expense↓-50.0% -$2K
$2K
Interest Income↓-1700.0% -$34K
$-32K
Other Income/Expense↓-51.5% -$35K
$33K
Pretax Income↑+24.3% +$571K
$-2M
Tax Provision
$-483K
Net Income↓-50.0% -$890K
$-3M
Gross Margin
55169.8%
Operating Margin↓-186.5pts
-554.0%
Net Margin↓-184.2pts
-546.0%
Effective Tax Rate
20.5%
Deferred Tax Liabilities↓-35.7% -$7M
$13M
NOL Carryforwards↑+13.1% +$2M
$16M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↑+8.0pts
0.5%
ETR Foreign Differential (pp)
—
Operating Lease Cost
$46K
Revenue YoY Variation
26.9%
Income YoY Variation↓-75.1pts
-49.8%
Revenue QoQ Variation↑+22.6pts
4.3%
Income QoQ Variation↑+38.1pts
21.5%